lamivudine/zidovudine fixed-dose combination (Combivir®) (No: 569/09)

GlaxoSmithKline UK Ltd

Product Update

07 August 2009

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

lamivudine/zidovudine fixed dose combination (Combivir®) in antiretroviral combination therapy is accepted for use within NHS Scotland for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) in paediatric patients weighing 14kg to 30kg.

This combination is listed in the British National Formulary for Children for the treatment of HIV infection. It was previously licensed for use in adults and adolescents weighing at least 30kg. The availability of both the combination product and its active ingredients pre-date the establishment of the Scottish Medicines Consortium.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 17 June 2009.

Chairman
Scottish Medicines Consortium

Published 07 September 2009

Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP
Telephone 0141 225 6989
E-mail: rosie.murray@nhs.net

Chairman Professor Kenneth R Paterson